Multiple myeloma: Recognition and management

American Family Physician

Volumn 59, Issue 7, 1999, Pages 1885-1892

  George, Enitza D ^a   Sadovsky, Richard ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYCLOPHOSPHAMIDE; DOXORUBICIN; MELPHALAN; PAMIDRONIC ACID; PREDNISONE; RECOMBINANT ALPHA2B INTERFERON; VINCRISTINE; VINCRISTINE SULFATE;

BONE MARROW TRANSPLANTATION; BONE PAIN; BONE RADIOGRAPHY; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG EFFICACY; HEAVY CHAIN DISEASE; HUMAN; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NEUTROPENIA; PATHOPHYSIOLOGY; PLASMACYTOMA; PROGNOSIS; REVIEW; WALDENSTROEM MACROGLOBULINEMIA;

DIAGNOSIS, DIFFERENTIAL; HUMANS; MULTIPLE MYELOMA; PATIENT EDUCATION; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TEACHING MATERIALS;

EID: 0033118994     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Kyle RA. Multiple myeloma: how did it begin? Mayo Clin Proc 1994;69:680-3.
2. Ishida T, Dorfman HD. Plasma cell myeloma in unusually young patients. Skeletal Radiol 1995;24: 47-51.
3. Walker B, Figgs LW, Zahm SH. Differences in cancer incidence, mortality, and survival between African Americans and whites. Environ Health Perspect 1995;103(suppl 8):275-81.
4. Bergsagel D. The incidence and epidemiology of plasma cell neoplasms. Stem Cells 1995;13(suppl 2):1-9.
5. Koessel SL, Theis MK, Vaughan TL, Koepsell TD, Weiss NS, Greenberg RS, et al. Socioeconomic status and the incidence of multiple myeloma. Epidemiology 1996;7:4-8.
6. Fritschi L, Siemiatycki J. Lymphoma, myeloma and occupation. Int J Cancer 1996;67:498-503.
7. Preston DL, Kusumi S, Tomonaga M, Izumi S, Ron E, Kuramoto A, et al. Cancer incidence in atomic bomb survivors. Radiat Res 1994; 137(2 suppl):S68-97 [Published erratum in Radiat Res 1994;139:129].
8. Cardis E, Gilbert ES, Carpenter L, Howe G, Kato I, Armstrong BK, et al. Effects of low doses and low dose rates of external ionizing radiation: cancer mortality among nuclear industry workers in three countries. Radiat Res 1995;142:117-32.
9. Cocco P, Blair A, Congia P, Saba G, Flore C, Ecca MR, et al. Proportional mortality of dichlorodiphenyl-trichloroethane (DDT) workers: a preliminary report. Arch Environ Health 1997;52:299-303.
10. Paxton MB, Chinchilli VM, Brett SM, Rodricks JV. Leukemia risk associated with benzene exposure in the pliofilm cohort: I. Mortality update and exposure distribution. Risk Anal 1994;14:147-54.
11. Flaitz CM, Hicks MJ. Molecular piracy: the viral link to carcinogenesis. Oral Oncol 1998;34(6):448-53.
12. Bakkus MH, Van Riet I, Van Camp B, Thielemans K. Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Br J Haematol 1994;87:68-74.
13. Feinman R, Sawyer J, Hardin J, Tricot G. Cytogenetics and molecular genetics in multiple myeloma. Hematol Oncol Clin North Am 1997;11:1-25.
14. Teoh G, Anderson KC. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am 1997; 11:27-42.
15. Munshi N. Immunoregulatory mechanisms in multiple myeloma. Hematol Oncol Clin North Am 1997;11:51-69.
16. Chauveau D, Choukroun G. Bence Jones proteinuria and myeloma kidney [Editorial). Nephrol Dial Transplant 1996;11:413-5.
17. Dhodapkar M, Merlini G, Solomon A. Biology and therapy of immunoglobulin deposition diseases. Hematol Oncol Clin North Am 1997;11:89-110.
18. Riccardi A, Gobbi P, Ucci G, Bertoloni D, Luoni R, Rutigliano L, et al. Changing clinical presentation of multiple myeloma. Eur J Cancer 1991;27:1401-5.
19. Bigos SJ, ed. Acute low back problems in adults. Rockville, Md.: U.S. Dept of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1994; AHCPR publication no. 95-0642.
20. Shami MJ, Uy RN. Isolated cotton-wool spots in a 67-year-old woman. Surv Ophthalmol 1996;40: 413-5.
21. Kyle RA. The monoclonal gammopathies. Clin Chem 1994;40(11 pt 2):2154-61.
22. Ravaud P, Thepot C, Auleley GR, Amor B. Imaging of multiple myeloma. Ann Med Interne [Paris] 1996;147:370-5.
23. Masciocchi C, D'Archivio C, Barile A, Fascetti E, Di Giovanni S, Beomonte Zobel B, et al. Magnetic resonance in the staging of multiple myeloma [Italian]. Radiol Med [Torino] 1992;83:561-8.
24. Boccadoro M, Pileri A. Diagnosis, prognosis, and standard treatment of multiple myeloma. Hematol Oncol Clin North Am 1997;11:111-31.
25. Bergsagel D. The incidence and epidemiology of plasma cell neoplasms. Stem Cells 1995;13 (suppl 2):1-9.
26. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975;36:842-54.
27. Awisati G, Petrucci MT. Is alpha-interferon treatment in multiple myeloma worthwhile? Stem Cells 1995;13(suppl 2):106-13.
28. Wallington M, Mendis S, Premawardhana U, Sanders P, Shahsavar-Haghighi K. Local control and survival in spinal cord compression from lymphoma and myeloma. Radiother Oncol 1997;42:43-7.
29. Berenson JR. Bisphosphonates in multiple myeloma. Cancer 1997;80(8 suppl):1661-7.
30. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998;16:593-602.
31. Attal M, Harousseau JL. Standard therapy versus autologous transplantation in multiple myeloma. Hematol Oncol Clin North Am 1997;11:133-46.